Personalized membrane protein vaccine based on a lipid nanoparticle delivery system prevents postoperative recurrence in colorectal cancer models
Acta Biomaterialia · 2025
DOI: 10.1016/j.actbio.2024.12.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2025. Verfasst von Guangzhao Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department: Digestive Medicine Centre, Guangdong Provincial Key Laboratory of Digestive Cancer Research, Institution: The Seventh Affiliated Hospital…. Hauptthemen laut MEDLINE: Cancer Vaccines, Carcinoma, Colorectal Neoplasms, Nanovaccines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Guangzhou University of Chinese Medicine International Institute for Translational Chinese Medicine, Sanming Project of Medicine in Shenzhen.
Abstract (Originalsprache)
While accessing tumor neoantigens and developing effective delivery systems have posed significant challenges in therapeutic oncology vaccines, this study introduces a cost- and time-efficient personalized tumor vaccine demonstrating potent anti-tumor effects in a mouse xenograft model. This vaccine utilizes a lipid nanoparticle (C5 LNP) system loaded with membrane protein antigens (mAg) derived from surgically excised tumor tissue. Its safety and efficacy were validated in a B16-OVA murine model. C5/OVA exhibited significant uptake by dendritic cells (DCs), leading to cross-presentation, maturation, and subsequent initiation of robust cell-mediated and humoral immune responses. This resulted in clear tumor growth suppression and extended survival in the B16-OVA model. Furthermore, the personalized C5/mAg vaccine effectively inhibited tumor growth in a colorectal carcinoma model. When combined with anti-PD-1 therapy, it notably increased complete remission (CR) rates in the CT26 xenograft model. Vaccinated mice demonstrated 100 % resistance to tumor rechallenge, underscoring the vaccine's ability to induce long-term immune memory. This study presents a promising personalized cancer vaccine delivery system with potential for both treatment and prevention of carcinoma in clinical applications. STATEMENT OF SIGNIFICANCE: In this paper, we present a scheme for manufacturing personalized tumor vaccines. The vaccine component consists of lipid nanoparticles (LNPs) designated C5 and membrane protein antigens (mAg) derived from autologous tumor tissue surgically resected from the patient. Our study demonstrates that the personalized mAg-C5 vaccine for colorectal carcinoma significantly inhibits tumor growth. Furthermore, conjugation with anti-PD-1 therapy demonstrably increased the complete remission (CR) rate in the murine CT26 xenograft tumor model. Additionally, mice treated with the C5/mAg vaccine exhibited 100 % resistance to tumor growth in a colon carcinoma rechallenge model, indicating the induction of immune memory by the vaccine. Our research results suggest that the mAg-LNP vaccine is a simple, cost-effective treatment that clinicians can easily and quickly integrate into routine practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department: Digestive Medicine Centre, Guangdong Provincial Key Laboratory of Digestive Cancer Research, Institution: The Seventh Affiliated Hospital Sun Yat-sen University, No.628, Zhenyuan Road, Guangming District, Sh…
- Department: Scientific Research Center, Institution: The Seventh Affiliated Hospital Sun Yat-sen University, No.628, Zhenyuan Road, Guangming District, Shenzhen, Guangdong CN518107, PR China.
- Department: Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, Institution: The Seventh Affiliated Hospital Sun Yat-sen University, No.628, Zhenyuan Road, Guangming District, Shenzhen, Guan…
- Department: Research and development center, Institution: Shenzhen MagicRNA Biotech, No.459, Qiaokai Road, Guangming District, Shenzhen, Guangdong CN518107, PR China.
Förderung
- Guangzhou University of Chinese Medicine International Institute for Translational Chinese Medicine
- Sanming Project of Medicine in Shenzhen
Zitieren
APA
Shi, G., Xu, Y., Qiu, H., Cao, F., Xiao, Z. X., Zhang, C., & Zha, G. F. (2025). Personalized membrane protein vaccine based on a lipid nanoparticle delivery system prevents postoperative recurrence in colorectal cancer models. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2024.12.003
Vancouver
Shi G, Xu Y, Qiu H, Cao F, Xiao ZX, Zhang C, et al. Personalized membrane protein vaccine based on a lipid nanoparticle delivery system prevents postoperative recurrence in colorectal cancer models. Acta Biomaterialia. 2025. doi:10.1016/j.actbio.2024.12.003
BibTeX
@article{Shi2025,
author = {Shi, Guangzhao and Xu, Yuandong and Qiu, Haowei and Cao, Fei and Xiao, Ze-Xiu and Zhang, Changhua and Zha, Gao-Feng},
title = {Personalized membrane protein vaccine based on a lipid nanoparticle delivery system prevents postoperative recurrence in colorectal cancer models},
journal = {Acta Biomaterialia},
year = {2025},
doi = {10.1016/j.actbio.2024.12.003}
}
EUVIMED